DMT Entities

Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial

Small Pharma Implements Cost-Cutting Strategy To Reduce Cash Burn As Trial Progresses

Small Pharma's IP Portfolio Grows With Numerous Approved Patent Applications Around The World

Small Pharma Implements Cost-Cutting Strategy To Reduce Cash Burn As Trial Progresses

Small Pharma's IP Portfolio Grows With Numerous Approved Patent Applications Around The World

Novel DMT Compound For Anxiety Shows Clinical Progress: Robust Effects Within 2 Minutes

Trial On DMT Drug For Anxiety And Depression Ends Participant Dosing, Study Results Soon Released

Novel DMT Compound For Anxiety Shows Clinical Progress: Robust Effects Within 2 Minutes

Trial On DMT Drug For Anxiety And Depression Ends Participant Dosing, Study Results Soon Released

Could DMT Therapy Be The Future Of Brain Injury Treatment? This Study Has Promising Results

Intravenous DMT Therapy Seeks Ideal Dosage For Stroke And TBI Treatment

DMT Entities Recent News

Small Pharma Inc: Positive Clinical Data For Major Depressive Disorder, Upcoming Virtual Roundtable

Short-acting psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) shared positive outcomes from its Phase 2a study of SPL026, the first placebo-controlled trial of the DMT-based short-duration psychedelic compound for the treatment of Major Depressive Disorder (MDD).

Development Of DMT Transdermal Patch With Eye Disease Treatment In Mind

Specialty R&D psychedelics company PharmaDrug Inc. (OTCQB: LMLLF) has inked a research collaboration agreement with PharmaTher Holdings Ltd. (OTCMKTS: PHRRF) to evaluate the delivery of DMT through PharmaTher's microneedle patch technology.

Developing Psychedelic Treatments For Traumatic Brain Injury: Algernon Launches New Program

Biopharma company Algernon Pharmaceuticals (OTCQB: AGNPF) has launched a new clinical research program via a subsidiary.

Algernon Touts Positive Study Findings, Confirms Next Trial Phase With Escalated Dose

Algernon Pharmaceuticals (OTCQB: AGNPF)’s subsidiary Algernon NeuroScience has completed the first cohort in its Phase 1 clinical study of

Short-Acting Psychedelics: DMT-Based Drug Therapy Gets Tested In New Clinical Trial

Psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) has dosed the first subject in its first-in-human clinical trial assessing proprietary DMT drug SPL028 paired with supportive therapy.

Cybin Reports Q3 Earnings, Says Psilocybin Tial Is Progressing As MDD Treatment

Cybin Inc. (NYSE: CYBN) has shared its unaudited financial results for the third quarter that ended Dec. 31, 2022. The company held total cash of $16.9 (CA$22.5) million as of Dec. 31, 2022, and $15 million as of Feb. 14, 2023.

Race Is On For Psychedelic DMT-Related Compounds, Small Pharma, Inc To Issue Two New Patents

After the positive results provided by its clinical trial assessing novel DMT’s effects on patients with Major Depressive Disorder (MDD), psychedelics biotech Small Pharma Inc.

Small Pharma, Inc's Psychedelics For Major Depression Trial Results And Q1 Earnings

Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF)’s proprietary intravenous (IV) DMT-based drug SPL026 delivered positive topline results in a Phase 2a trial for the treatment of Major Depressive Disorder (MDD).

Psychedelics Companies Join The Race To Develop Much-Needed Anxiety Treatment

Life sciences biotech company Cybin Inc. (NYSE: CYBN) announced its selection of the Generalized Anxiety Disorder (GAD) with or without Major Depressive Disorder (MDD) as the target indication for its proprietary deuterated DMT molecule, CYB004.

Encountering DMT Entities: Are They Real?

This article was originally published on Psychedelic Spotlight and appears here with permission. DMT is a powerful hallucinogen famous for producing experiences of encounters with entities, but how many people actually see them?